Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. freshman Avg
|
New words:
accident, acroparesthesia, alter, antibody, antidrug, antimicrobial, ATM, attest, autoimmune, behavior, BofA, BPI, CECL, CKD, Clarifying, cohort, composed, contemplate, covalently, cybersecurity, distancing, Dyadic, dyspnea, EAP, easement, Eighteen, elevate, Elitek, elongate, elongated, epidemic, fibrotic, filer, flare, Hackensack, Hayon, headache, heat, hospital, hypersensitivity, hyperuricemia, ineffective, infarction, Inferior, interaction, interference, intolerance, kill, Kirin, Ligand, magnitude, myocardial, NaN, Neutrophil, notification, OfferingSM, Oppenheimer, outbreak, pandemic, pathological, PDUFA, PEG, permanent, persistent, Pfenex, postpone, premature, prolonged, proportionately, questionnaire, quick, reaction, reader, refractory, relapse, respiratory, reveal, SarcoMed, SD, SE, setup, slightly, soft, strongly, sUA, survey, topline, traffic, trap, troubled, Twenty, uncertain, underwriting, Undetected, weakening, withdrew, Wuhan, Yael
Removed:
Aaron, AbbVie, Academy, Accountant, activation, affirmative, Agriculture, Alexander, Angel, Appen, area, Arntzen, attend, attribute, biochemistry, biology, biomedical, bowel, capsule, causa, cellulose, Certification, Chair, Ciechanover, Comercio, conjunction, consolidate, consult, correlated, crohn, cured, daily, def, degradation, desirable, deteriorate, digestive, dispose, distinguished, Doctor, effecton, EFMC, Ely, Enbrel, exceeded, Factor, Faculty, Figure, Florence, fourth, French, fusion, GalafoldTM, GlycoFi, glycosilation, gradual, gut, Hamered, Hebrew, hinder, Humira, IBD, immune, Importantly, induction, inInternal, INSTANCE, Institute, introducing, issuing, Jerusalem, Kesselman, Kornberg, Lastly, Laureate, leadership, Leopold, Levitzki, Ltda, Manor, Mayer, Mayo, media, Medicine, Mellon, Merck, merge, mg, Mine, Moshe, Nauta, Nelson, Nobel, North, ofpegunigalsidase, orally, organ, Park, passing, Pharmacochemistry, PK, positivity, PPACA, Presidential, Prize, Profession, Professor, protest, qualitative, Rappaport, rebate, rectal, refinance, regain, Regent, registrar, remeasure, Remicade, remission, Renewable, resistant, rheumatoid, Roger, science, settlement, Shlomo, Silberman, sorting, Stanford, Structural, Supplementary, suppression, surface, Technion, telephone, temporary, Tower, tract, trust, turned, ulcerative, University, Unprotected, Unresolved, unvested, Vascular, violence, voluntary, wall, wealth, Welch, Winzer, Wolfson, XBRL, Yanai, York
Filing tables
Filing exhibits
Related press release
Associated PLX transcripts
PLX similar filings
Filing view
External links
Exhibit 23.1
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We hereby consent to the incorporation by reference in the Registration Statements on Form S-3 (No. 333-230604 and 333-237736) and on Form S-8 (No. 333-148983, No. 333-182677, No. 333-203960, No. 333-225526 and No. 333-239101) of Protalix BioTherapeutics, Inc. of our report dated March 30, 2021 relating to the financial statements, which appears in this Form 10-K.
/s/ Kesselman & Kesselman |
|
|
Kesselman & Kesselman |
Certified Public Accountants (lsr.) |
A member firm of PricewaterhouseCoopers International Limited |
|
|
Tel-Aviv, Israel |
March 30, 2021 |